Isomorphic Labs Raises $2.1 Billion To Scale AI Drug Discovery
Alphabet-backed Isomorphic Labs has raised $2.1 billion to expand its AI drug discovery platform and advance medicines into clinical trials.
The race to use artificial intelligence for designing medicines is rapidly becoming one of the most expensive and closely watched bets in technology and biotech.
On 12 May 2026, Isomorphic Labs announced a $2.1 billion Series B funding round, roughly Rs 17,400 crore at prevailing exchange rates, marking one of the largest financings yet for an AI-first drug discovery company.
According to the company, the fresh capital will help scale its AI drug design platform and push AI-created medicines closer to human clinical testing.
A massive new funding round
The London-headquartered company said the Series B round was led by Thrive Capital, with participation from existing investors Alphabet and GV. New investors included CapitalG, Temasek, MGX, and the UK Sovereign AI Fund.
Isomorphic Labs stated the funding will support expansion of its AI platform, hiring across research and engineering, and advancement of both partnered and internal drug programmes toward first-in-human clinical studies.
The company also said it plans to continue scaling operations across London, Cambridge, Massachusetts, and Lausanne in Switzerland.
Why investors are betting heavily on AI-designed medicines
The scale of the financing reflects growing confidence that AI systems may eventually transform how medicines are discovered and developed. Traditional drug discovery is notoriously slow, expensive, and failure-prone.
Pharmaceutical companies often spend years screening compounds before identifying viable candidates for clinical testing. Isomorphic Labs argues that AI can dramatically compress those cycles by predicting which molecules are most likely to succeed before extensive laboratory work begins.
Industry reports suggest the company is targeting its first human clinical trials by late 2026, although earlier expectations had pointed to an end-2025 timeline. Analysts say the revised target reflects the complexity of converting AI-generated predictions into clinically validated therapies.
Still, the funding round signals that investors increasingly see AI as more than a research assistant inside biotech. Many now view it as a potential development engine capable of reshaping the economics of drug creation itself.
Built out of DeepMind’s research
Founded in 2021 as a spin-out from Google DeepMind, Isomorphic Labs has steadily expanded its position in AI-enabled biology and pharmaceutical research. The company gained global attention after DeepMind’s AlphaFold system demonstrated breakthroughs in protein structure prediction.
Isomorphic Labs has since attempted to extend that work into full-scale drug discovery workflows. In January 2024, the company announced partnerships with Eli Lilly and Novartis worth nearly $3 billion in potential milestone payments. It later raised $600 million in 2025 to accelerate programmes toward the clinic.
Earlier this year, the company introduced the Isomorphic Labs Drug Design Engine, or IsoDDE, which it describes as an integrated AI platform capable of designing, ranking, and refining potential drug candidates across multiple biological targets and modalities.
How the AI drug design engine works
According to the firm, IsoDDE combines foundational AI models with medicinal chemistry and biology workflows. At a broad level, the system analyses vast biological and chemical datasets to understand how proteins are shaped and where therapeutic molecules are most likely to bind effectively.
Once researchers define a target, the AI proposes and prioritises candidate molecules based on predicted potency, selectivity, and other pharmaceutical properties. Scientists then synthesise and test the most promising compounds in laboratories. Experimental results are fed back into the models, helping improve future predictions and reduce wasted iterations.
The company says the aim is to eliminate dead-end candidates earlier in the process and concentrate resources on compounds with the highest probability of success. Industry observers say this feedback-loop approach is increasingly becoming central to next-generation AI drug discovery platforms.
Leadership sees AI as the future of biology
Demis Hassabis, founder and chief executive of Isomorphic Labs, has repeatedly framed AI as a foundational tool for industrialising biology and accelerating medicine creation. The company's latest financing gives it the resources to move from computational discovery into real-world therapeutic development.
President Max Jaderberg is overseeing platform and operational expansion as the company scales. Leadership maintains that combining frontier AI systems with pharmaceutical expertise is essential for translating computational breakthroughs into medicines that work safely in humans.
AI in healthtech: Why a fine balance between innovation and data privacy is crucial
The next phase begins in the clinic
The real test for Isomorphic Labs now lies beyond simulations and algorithms. AI-generated compounds still need to survive clinical validation, one of the most difficult stages in drug development. Investors and pharmaceutical partners will closely watch whether the company can demonstrate meaningful human outcomes as its programmes move into trials.
At the same time, the financing signals that AI drug discovery has entered a new competitive phase. Large technology companies, pharmaceutical firms, and investors are increasingly treating AI-enabled biology as one of the most commercially important frontiers in healthcare.
If Isomorphic Labs succeeds in moving AI-designed medicines into human studies by late 2026, it could accelerate funding, partnerships, and competition across the entire sector. If progress proves slower, the industry will likely demand more transparent data and clearer proof that AI can consistently improve real-world drug development outcomes.
Either way, the scale of this raise shows that AI drug discovery is no longer an experimental side project. It is becoming one of the defining races in modern biotechnology.